We are live on ! Find out more
NRIX icon

Nurix Therapeutics

130 hedge funds and large institutions have $476M invested in Nurix Therapeutics in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

843% more call options, than puts

Call options by funds: $575K | Put options by funds: $61K

18% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 38

12% more capital inflows, than outflows

Capital inflows: $54.6M | Capital outflows: $48.9M

2.02% more ownership

Funds ownership: 92.99% → 95.01% (+2%)

2% more funds holding

Funds holding: 128 → 130 (+2)

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

Holders
130
Holders Change
+2
Holders Change %
+1.56%
% of All Funds
1.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
45
Reduced
38
Closed
23
Calls
$575K
Puts
$61K
Net Calls
+$514K
Net Calls Change
+$498K

NRIX Hedge Fund Activity: Q4 2023 in Review

130 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2023, worth a combined $476M — up 35% from $352M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new NRIX positions and 23 closed out — a net gain of 2 holders — while 45 added to existing stakes and 38 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $19.7M. The largest seller was Boxer Capital, exiting entirely with an estimated $9.6M sold.

  • 130 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2023, up from 128 in Q3 2023.
  • Funds reported $476M of Nurix Therapeutics stock for Q4 2023, up 35% quarter-over-quarter.
  • 25 funds opened new Nurix Therapeutics positions in Q4 2023 and 23 closed out, a net change of +2 holders.
  • The largest Nurix Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $19.7M added.
  • The largest Nurix Therapeutics seller in Q4 2023 was Boxer Capital, an estimated $9.6M sold.

Based on aggregated 13F filings for Q4 2023.